O'Day Steven J 4

What Happened

• Steven J. O'Day, Chief Medical Officer of Agenus Inc. (AGEN), was granted two derivative awards (stock options) on April 24, 2026 totaling 165,333 shares: 70,000 and 95,333 options. The Form 4 reports an acquisition price of $0, indicating these were granted awards rather than an open‑market purchase or sale.

Key Details

• Transaction date: April 24, 2026 (reported on Form 4 filed April 28, 2026).
• Awards: 70,000 options (Footnote F1) and 95,333 options (Footnote F2); combined = 165,333 options.
• Reported price: $0.00 (award/grant of derivatives).
• Vesting: F1 vests over three years (one‑third on April 24, 2027, then remaining in equal quarterly installments); F2 vests in full on May 24, 2026.
• F2 was awarded in lieu of the 2025 annual cash bonus.
• Shares owned after transaction: not specified in the filing.
• No sale or exercise reported — these are grants, not dispositions.

Context

• These are option awards (derivative securities) intended for compensation/retention. They do not represent immediate proceeds or open‑market buying/selling; value to the insider depends on future exercise price and stock performance. For retail investors, option grants signal executive compensation decisions but are not direct bullish/bearish trades on the open market.